Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Niraparib + SY-1365|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 21||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|SY-1365||SY1365||CDK7 Inhibitor 14||SY-1365 is a selective CDK7 inhibitor that induces apoptosis in tumor cells (PMID: 31064851, PMID: 32150405).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Niraparib + SY-1365||Preclinical - Cell culture||Actionable||In a preclinical study, SY-1365 and Zejula (niraparib) synergistically induced apoptosis in triple-receptor negative breast cancer cells in culture (Proceedings of the AACR, Vol 58, April 2017, Abstract # 1151).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|